InnoCare Pharma Ltd.
http://www.innocarepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InnoCare Pharma Ltd.
Lockdown To Reopening: China Rebound Uncertain As Biotech Remains In Survival Mode
The short-notice reopening of the country made 2022 a tough year for the health sector in China, where divestments, cash crunches and commercial challenges abounded. Throughout the year, despite clinical trial activity continuing to blossom, multiple Chinese innovative drug developers faced setbacks in the US from regulatory rejections of oncology products. Meanwhile, others quietly scaled back their operations in China, hit by the negative impact of deep price cuts.
China Closes In On Top 10 In Global Innovation Ranking
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.
Chinese Biotechs Feel Chill Wind Of Hesitant Investors
Large or small, Chinese biotechs are receiving the cold shoulder from some investors amid souring investment sentiment. HanBio, Frontier and InnoCare have all seen their fundraising efforts hampered to various degrees.
'Still The Place To Do Drug Innovation': China Biotech CEO Podcast With InnoCare’s Jasmine Cui
From founding to the approval and commercial launch of its first innovative drug took Beijing-based biotech InnoCare just seven years. After a listing in Hong Kong, the firm is now heading to Shanghai after obtaining the green light for a second listing from the STAR board.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Beijing InnoCare Pharma Tech Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice